Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

lachlan conference
September 3rd, 2024

What's Next for Clinuvel Pharmaceuticals?

Over the last seven years, Clinuvel Pharmaceuticals (CUV: $14.95) has generated around $330 million in sales from its pharmaceutical product Scenesse for the treatment of EPP. The compound annual growth rate in sales over the last six years has been 42% and the company has been profitable for the last seven years.

Pages